

Published in final edited form as:

Cochrane Database Syst Rev. ; (1): CD000262. doi:10.1002/14651858.CD000262.pub3.

Antibiotics for treating bacterial vaginosis in pregnancy

Helen Margaret McDonald², Peter Brocklehurst³, and Adrienne Gordon¹

¹RPA Newborn Care, RPA Women and Babies, Royal Prince Alfred Hospital, Sydney, Australia.

²Microbiology and Infectious Diseases, Women's and Children's Hospital, North Adelaide, Australia.

³National Perinatal Epidemiology Unit, University of Oxford, Headington, UK

Abstract

Background—Bacterial vaginosis is an imbalance of the normal vaginal flora with an overgrowth of anaerobic bacteria and a lack of the normal lactobacillary flora. Bacterial vaginosis during pregnancy has been associated with poor perinatal outcome and, in particular, preterm birth (PTB). Identification and treatment may reduce the risk of PTB and its consequences.

Objectives—To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy.

Search methods—We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (May 2006). We updated this search on 18 November 2010 and added the results to the awaiting classification section.

Selection criteria—Randomized trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora.

Data collection and analysis—Two review authors assessed trials and extracted data independently. We contacted study authors for additional information.

Main results—We included fifteen trials of good quality, involving 5888 women. Antibiotic therapy was effective at eradicating bacterial vaginosis during pregnancy (Peto odds ratio (OR) 0.17, 95% confidence interval (CI) 0.15 to 0.20; 10 trials, 4357 women). Treatment did not reduce the risk of PTB before 37 weeks (Peto OR 0.91, 95% CI 0.78 to 1.06; 15 trials, 5888 women), or the risk of preterm prelabour rupture of membranes (PPROM) (Peto OR 0.88, 95% CI 0.61 to

Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd

Contact address: Adrienne Gordon, RPA Newborn Care, RPA Women and Babies, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia. adrienne.gordon@email.cs.nsw.gov.au.

CONTRIBUTIONS OF AUTHORS Helen McDonald (HM), as the new contact author from 2003, was responsible for performing searches; personal communications with researchers; extracted and entered data; revised text and responded to comments, etc, for the second and third reviews. HM is the guarantor for the review.

Peter Brocklehurst, as contact author for the first review, was primarily responsible for writing the text, responding to comments, etc. As co-author for the second and third reviews, he reviewed studies and contributed to the revised text.

Adrienne Gordon, co-author for the third review, reviewed studies, extracted data, performed double entry of data, restructured tables, and contributed to the revised text for the third review.

Editorial group: Cochrane Pregnancy and Childbirth Group.

Publication status and date: Edited (no change to conclusions), published in Issue 1, 2011.

Review content assessed as up-to-date: 24 September 2006.

DECLARATIONS OF INTEREST Helen McDonald is the author of one of the included trials in this review.

1.28; four trials, 2579 women). However, treatment before 20 weeks' gestation may reduce the risk of preterm birth less than 37 weeks (Peto OR 0.72, 95% CI 0.55 to 0.95; five trials, 2387 women). In women with a previous PTB, treatment did not affect the risk of subsequent PTB (Peto OR 0.83, 95% CI 0.59 to 1.17, five trials of 622); however, it may decrease the risk of PPRM (Peto OR 0.14, 95% CI 0.05 to 0.38) and low birthweight (Peto OR 0.31, 95% CI 0.13 to 0.75)(two trials, 114 women). In women with abnormal vaginal flora (intermediate flora or bacterial vaginosis) treatment may reduce the risk of PTB before 37 weeks (Peto OR 0.51, 95% CI 0.32 to 0.81; two trials, 894 women). Clindamycin did not reduce the risk of PTB before 37 weeks (Peto OR 0.80, 95% CI 0.60 to 1.05; six trials, 2406 women).

Authors' conclusions—Antibiotic treatment can eradicate bacterial vaginosis in pregnancy. This review provides little evidence that screening and treating all pregnant women with asymptomatic bacterial vaginosis will prevent PTB and its consequences. However, there is some suggestion that treatment before 20 weeks' gestation may reduce the risk of PTB. This needs to be further verified by future trials.

[Note: The eleven citations in the awaiting assessment section of the review may alter the conclusions of the review once assessed.]

Medical Subject Headings (MeSH)

Anti-Bacterial Agents [*therapeutic use]; Pregnancy Complications, Infectious [*drug therapy]; Premature Birth [*prevention & control]; Randomized Controlled Trials as Topic; Vaginosis, Bacterial [*drug therapy]

MeSH check words

Female; Humans; Pregnancy

BACKGROUND

Bacterial vaginosis is an imbalance of vaginal flora caused by a reduction of the normal lactobacillary bacteria, and a heavy over-growth of mixed anaerobic flora including *Gardnerella vaginalis*, *Mycoplasma hominis* and *Mobiluncus* species. Why these organisms multiply, many of which are normally present in small numbers in the vagina, while the usually prevalent lactobacilli decrease, is not clear. The role of hydrogen peroxide-producing lactobacilli appears to be important in preventing overgrowth of anaerobes in normal vaginal flora (Hillier 1993). Bacterial vaginosis does not appear to be sexually transmitted but may be associated with sexual activity.

Bacterial vaginosis is often asymptomatic but may result in a vaginal discharge which can be grey in colour with a characteristic 'fishy' odour. It is not associated with vaginal mucosal inflammation and rarely causes vulval itch.

The classical diagnosis of bacterial vaginosis is confirmed by fulfilling three out of four criteria (Amsel 1983). These are (i) a vaginal pH greater than 4.7, (ii) the presence of 'clue cells' on a Gram stain or wet mount of the vaginal discharge, (iii) the presence of a thin homogenous discharge and (iv) the release of a fishy odour when potassium hydroxide is

added to a sample of the discharge. The use of these criteria for diagnosis, however, is complex and time consuming. Use of a Gram stain of a vaginal swab with semi-quantification of the microbial flora has high sensitivity and specificity and is an accepted alternative method which has been used in many studies (Nugent 1991). Scoring systems which weight low numbers or the absence of lactobacilli and large numbers of Gram negative/Gram variable bacilli are routinely used in the clinical laboratory for the diagnosis of bacterial vaginosis from a Gram stain. Clue cells may be present but are not mandatory. The Nugent classification includes an “intermediate” group of women with abnormal genital tract colonisation (reduced lactobacilli and intermediate flora) which may be a transition stage on the way to fully fledged bacterial vaginosis.

Natural history in pregnancy

Bacterial vaginosis is present in up to 20% of women during pregnancy (Lamont 1993). The majority of these cases will be asymptomatic. The natural history of bacterial vaginosis is such that it may spontaneously resolve without treatment although most women identified as having bacterial vaginosis in early pregnancy are likely to have persistent infection later in pregnancy (Hay 1994).

There is now a substantial body of evidence associating bacterial vaginosis in pregnancy with poor perinatal outcome, in particular an increased risk of preterm birth (Hay 1994a; Hillier 1995; Kurki 1992; McGregor 1990), with potential neonatal sequelae due to prematurity. There is also evidence associating intermediate flora with adverse pregnancy outcome (Hay 1994a). Whilst a number of other genital micro-organisms such as *Escherichia coli*, *Listeria monocytogenes* and viridans streptococci may be involved in chorioamnionitis, carriage of these organisms during early to mid pregnancy has not been associated with an increased risk of preterm labour. Although maternal carriage of group B streptococcus increases the risk of neonatal sepsis due to this organism, there is conflicting evidence about whether carriage during pregnancy increases the risk of preterm birth. Infections during pregnancy for which there is good evidence of an increased risk of preterm birth and preterm prelabour rupture of the membranes, include asymptomatic bacteriuria, *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Trichomonas vaginalis* and bacterial vaginosis. The opportunity therefore exists to reduce the preterm birth rate by treatment of these infections during pregnancy.

Bacterial vaginosis is relatively common, even in populations of women at low risk of adverse events and, as it is amenable to treatment (Burtin 1995; Fischbach 1993; McDonald 1994), identification during pregnancy and treatment may present a rare opportunity to reduce the preterm birth rate, and resulting risk of prematurity to the newborn. Such treatment may also reduce other adverse perinatal outcomes such as postpartum infection. However, the question of why bacterial vaginosis is associated with preterm birth in some women but not in others remains unanswered and the exact mechanism by which the organisms associated with bacterial vaginosis may effect the initiation of preterm labour remains unclear. Recent evidence indicates individual susceptibility to preterm birth or intrauterine infection, or both, may be increased by the presence of specific gene polymorphisms (Annells 2004; Annells 2005; Simhan 2003; Witkin 2003). Hence the results

of randomized controlled trials of treatment are needed to provide more direct evidence of the role of bacterial vaginosis in preterm birth.

OBJECTIVES

To determine whether the use of antibiotics for bacterial vaginosis in pregnancy can:

- a. improve maternal symptoms;
- b. decrease incidence of adverse perinatal outcomes.

To determine, if antibiotics are helpful, which antibiotic regimens are most effective.

METHODS

Criteria for considering studies for this review

Types of studies—All randomized controlled trials that compare (i) one antibiotic regimen with placebo or no treatment or (ii) two or more alternative antibiotic regimens in pregnant women with bacterial vaginosis (however defined).

Types of participants—Women of any age, at any stage of pregnancy with a diagnosis of bacterial vaginosis regardless of method of diagnosis (detected because of symptoms or asymptomatic as part of a screening programme). Co-infection with other sexually transmitted infections is not a reason to exclude a study from the review.

Types of interventions—Any antibiotic (any dosage regimen, any route of administration) compared with either placebo or no treatment.

Any two antibiotic regimens compared.

Types of outcome measures—The outcome measures in this review are as follows.

(A) Maternal symptoms

- (i) Clinical report by women of failure of symptoms to improve;
- (ii) failure to eradicate bacterial vaginosis on examination (failure to achieve 'microbiological cure');
- (iii) incidence of fever during labour or delivery;
- (iv) incidence of chorioamnionitis treated with antibiotics;
- (v) incidence of postpartum fever;
- (vi) incidence of postpartum uterine infection;
- (vii) incidence of pregnancy loss up to 24 weeks' gestation (late miscarriage).

(B) Neonatal outcomes**Clinical**

- (viii) Perinatal death including stillbirth after 24 weeks' gestation and neonatal death, up to 28 days after birth;
- (ix) severe neonatal morbidity (moderate to severe respiratory distress syndrome - defined as any ventilatory support, intraventricular haemorrhage, necrotising enterocolitis, chronic lung disease);
- (x) neonatal sepsis (defined as definite symptoms or positive cultures from a sterile site - positive culture of gastric aspirates alone will not be sufficient);
- (xi) incidence of preterm prelabour rupture of membranes;
- (xii) birth less than 37 weeks' gestation;
- (xiii) birth less than 34 weeks' gestation;
- (xiv) birth less than 32 weeks' gestation;
- (xv) incidence of low birthweight (however defined);
- (xvi) cerebral palsy at childhood follow up;
- (xvii) moderate/severe visual impairment at childhood follow up;
- (xviii) moderate/severe hearing impairment at childhood follow up;

Economic

- (xxii) Admission to neonatal unit;
- (xxiii) total duration of ventilatory support.

(C) Maternal side-effects

- (xxiv) Side-effects sufficient to stop or change treatment;
- (xxv) other side-effects not sufficient to stop or change treatment.

Search methods for identification of studies

Electronic searches—We searched the Cochrane Pregnancy and Childbirth Group's Trials Register by contacting the Trials Search Co-ordinator (May 2006). We updated this search on 18 November 2010 and added the results to the awaiting classification section.

The Cochrane Pregnancy and Childbirth Group's Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:

1. quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major conferences;

4. weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.

Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Specialized Register' section within the editorial information about the Cochrane Pregnancy and Childbirth Group.

Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.

Searching other resources—We applied no language restrictions. We searched cited references from retrieved articles for additional studies and reviewed abstracts and letters to the editor to identify randomized controlled trials that have not been published. We also reviewed editorials, indicating expert opinion, to identify and ensure that no key studies were missed for inclusion in this review.

Data collection and analysis

We selected all potential trials for eligibility according to the criteria specified in the protocol. Each of the authors independently abstracted the information necessary for the review from the report and, where necessary, we sought additional information from the authors.

We assessed all trials for methodological quality using the standard Cochrane criteria. As there are a sufficient number of trials in the review, we stratified the trials by quality to explore the robustness of the findings. We calculated summary Peto odds ratios when appropriate (ie there was no evidence of significant heterogeneity) using the Cochrane Review Manager software (RevMan 2003).

Stratified analysis—As there are sufficient trials in the review, the comparisons are stratified to explore the effect of the intervention on the outcomes by the following factors:

1. oral versus vaginal antibiotics;
2. women with a previous preterm birth;
3. women with intermediate flora/bacterial vaginosis;
4. clindamycin versus placebo treatment;
5. treatment before 20 weeks' gestation.

It was not possible to stratify results into symptomatic versus asymptomatic bacterial vaginosis because in most trials, women with symptoms were treated with antibiotics and were therefore excluded.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies.

Fifteen trials, involving 5888 women, are included. *See* table of 'Characteristics of included studies' for details.

Five trials used oral metronidazole alone, one used oral metronidazole plus erythromycin, one oral clindamycin, one ampicillin, one vaginal metronidazole gel, while six used intravaginal clindamycin. Ten trials performed microbiological follow up and seven trials gave a second course of treatment (four only if bacterial vaginosis was not eradicated). One trial compared different antibiotic regimens (once daily versus twice daily vaginal metronidazole).

Two trials which used intermediate vaginal flora (Nugent score four to six) as well as bacterial vaginosis as the basis for recruitment have been included as a separate comparison.

For details of excluded studies, *see* table of 'Characteristics of excluded studies'.

Risk of bias in included studies

Overall the quality of the trials was good. All but two of the trials were placebo controlled (one compared once daily versus twice daily regimens, although this was not completed (Porter 2001) and one compared treatment with no treatment (Guaschino 2003). One trial (Duff 1991) did not provide pregnancy outcome data. Eleven trials reported losses to follow up. The description of the interventions was good and the main outcome of all the trials was well described.

However, the interventions differed (oral, intravaginal, metronidazole, clindamycin) as did the timing of the intervention during pregnancy.

Two trials did not report an intention-to-treat analysis (Kiss 2004; Morales 1994). The Morales trial (Morales 1994) excluded women who were not compliant with the treatment allocated (6% of the total trial cohort). Two trials recruited women considered to be at risk of preterm labour on the basis of their past history of spontaneous preterm birth. They were allocated antibiotic or placebo and the results were stratified by whether they did or did not have bacterial vaginosis at that visit (the results of which were available after randomization) (Hauth 1995; Vermeulen 1999). Although this is not ideal, it is unlikely that any selection bias resulted from this process. In addition, in the latter trial only 11 women in each group had bacterial vaginosis. Another trial (Odendaal 2002) included primigravidae from the general population and women with a history of preterm birth or midtrimester miscarriage, or both. A further trial (McDonald 1997) included women with bacterial vaginosis or women with a heavy growth of *Gardnerella vaginalis*. Women with bacterial vaginosis have been included in this review. In the largest study to date (NICHD MFMU 2000), 1919 women were enrolled from the general population between 18 to 24 weeks, although in some women treatment was delayed up to eight weeks after the detection of

bacterial vaginosis, at which time one-quarter of the women in each group had a negative test for bacterial vaginosis. This high rate of spontaneous resolution may have reduced any measurable effect of antibiotic treatment on adverse pregnancy outcomes. A second study from this trial (NICHD MFMU 2001) has now been included containing data not included in the 2000 publication, ie women with *Trichomonas* and bacterial vaginosis. Two recent trials included women with reduced lactobacilli and intermediate flora as well as those with bacterial vaginosis (Lamont 2003; Ugwumadu 2003). These have been included because of evidence that women with intermediate vaginal flora are also at higher risk of preterm birth (Hay 1994a). In women with a previous preterm birth, the design of the trials varied. In two trials, women with a previous preterm birth were randomized and a subgroup of them had bacterial vaginosis (Hauth 1995; Vermeulen 1999). In a third trial, women with bacterial vaginosis were randomized and a subgroup of them had experienced a previous preterm birth (McDonald 1997). The fourth trial did not perform an intention-to-treat analysis (Morales 1994). The fifth trial (Odendaal 2002) enrolled women with a previous preterm birth or a previous midtrimester miscarriage as a separate arm of the trial. In the largest trial (NICHD MFMU 2000) a subgroup of 210 women had a previous preterm birth. (In another trial (Ugwumadu 2003) a subgroup of 74 had a previous preterm birth, however, because the data included late miscarriages and data for elective preterm births were not available, this study was not included here.) In the recent trial added in this update (Kiss 2004), a large number of women were excluded from the analysis; randomization was performed on all enrolled women and a sub-analysis of women with bacterial vaginosis was performed.

In two trials (Lamont 2003; Ugwumadu 2003) women with intermediate flora or bacterial vaginosis were considered to have abnormal genital tract flora and were randomized without distinction. These have been put into a separate sixth category for evaluation.

Effects of interventions

Fifteen trials involving 5888 women were included. The available evidence from these trials suggests that antibiotic treatment given to women with bacterial vaginosis in pregnancy is highly effective at eradicating bacterial vaginosis infection (Peto odds ratio (OR) 0.17, 95% confidence interval (CI) 0.15 to 0.20, 10 trials of 4357 women). There was significant heterogeneity between trials in this 'failure of test of cure' comparison, but using random-effects analysis makes very little difference to the result (Peto OR 0.14, 95% CI 0.08 to 0.25). The effect size is similar whether the antibiotic is given orally or vaginally, although there was no direct head to head comparison of oral versus vaginal treatment (Peto OR 0.15, 95% CI 0.13 to 0.17, seven trials of 3244 women and Peto OR 0.27, 95% CI 0.21 to 0.35, three trials of 1113 women).

There was no statistically significant decrease in the risk of preterm birth less than 37 weeks' gestation for any treatment versus no treatment or placebo (Peto OR 0.91, 95% CI 0.78 to 1.06, 15 trials of 5888 women). There was also no evidence of an effect on birth before 34 weeks (Peto OR 1.22, 95% CI 0.67 to 2.19, five trials of 851 women), nor for an effect on birth before 32 weeks (Peto OR 1.14, 95% CI 0.76 to 1.70, four trials of 3565 women). The effect of treatment on the incidence of low birthweight suggests no difference (Peto OR 0.95, 95% CI 0.77 to 1.17, seven trials of 4107 women). Antibiotics were not

associated with a decrease in the risk of preterm prelabour rupture of membranes (Peto OR 0.88, 95% CI 0.61 to 1.28 four trials of 2579 women), and there was significant heterogeneity between trials. Using random-effects analysis makes little difference to the result (Peto OR 0.71, 95% CI 0.25 to 1.97).

Very few perinatal deaths were reported and only one trial (NICHD MFMU 2000 unpublished) reported substantive measures of neonatal morbidity or economic outcomes such as health service utilisation.

Stratified analyses were possible for (a) whether the antibiotic treatment was oral or vaginal (b) whether the women had experienced a previous preterm birth and (c) whether the woman had intermediate vaginal flora (including bacterial vaginosis), (d) clindamycin treatment (e) treatment before 20 weeks' gestation.

(a) Oral and vaginal antibiotics—Vaginal antibiotics appear to have no effect on any measure of preterm birth: Peto OR 0.88, 95% CI 0.64 to 1.21 for birth less than 37 weeks (five trials of 1921 women); Peto OR 1.79, 95% CI 0.81 to 3.98 for birth less than 32 weeks (one trial of 681 women); and Peto OR 1.14, 95% CI 0.75 to 1.74 for low birthweight (three trials of 1181 women). Oral antibiotics were not associated with an effect on birth less than 37 weeks (Peto OR 0.90, 95% CI 0.75 to 1.08, eight trials of 4069 women, with significant heterogeneity between the studies), nor on preterm prelabour rupture of membranes (Peto OR 0.80, 95% CI 0.54 to 1.19, three trials of 2479 women), birth less than 34 weeks (Peto OR 1.30, 95% CI 0.72 to 2.35, three trials of 819 women), less than 32 weeks (Peto OR 0.98, 95% CI 0.61 to 1.55, three trials of 2884 women) or low birthweight (Peto OR 0.89, 95% CI 0.70 to 1.13, four trials of 2926 women).

(b) Women with a previous preterm birth—In women with a previous preterm birth, the use of antibiotics was associated with a statistically significant decreased risk of preterm prelabour rupture of membranes (Peto OR 0.14, 95% CI 0.05 to 0.38, two trials of 114 women), and low birthweight (Peto OR 0.31, 95% CI 0.13 to 0.75, two trials of 114 women). There is no evidence of an effect on birth less than 37 weeks (Peto OR 0.83, 95% CI 0.59 to 1.17, five trials of 622 women, with significant heterogeneity between these trials), birth less than 34 weeks (Peto OR 1.21, 95% CI 0.59 to 2.49, four trials of 257 women) nor on birth less than 32 weeks (Peto OR 0.49, 95% CI 0.05 to 5.08, one trial of 34 women).

(c) Intermediate flora including bacterial vaginosis—In two trials of 894 women with abnormal vaginal flora (intermediate flora or bacterial vaginosis), the use of antibiotics (one trial used oral clindamycin, the other vaginal) was associated with a statistically significant decreased risk of preterm birth less than 37 weeks (Peto OR 0.51, 95% CI 0.32 to 0.81). However there was no difference in other outcome measures such as preterm birth less than 32 weeks or low birthweight, etc.

(d) Clindamycin (oral or vaginal) treatment—Although Clindamycin may have more antimicrobial activity than metronidazole against *Mobiluncus* species (these are often present in bacterial vaginosis), in six trials of 2406 women clindamycin was effective

against bacterial vaginosis (Peto OR 0.14, 95% CI 0.12 to 0.18) but did not significantly lower the preterm birth rate before 37 weeks (Peto OR 0.80, 95% CI 0.60 to 1.05).

(e) Treatment before 20 weeks' gestation—In five trials of 2387 women who were treated before 20 weeks' gestation, the use of antibiotics was associated with a statistically significant decreased risk of preterm birth less than 37 weeks (Peto OR 0.72, 95% CI 0.55 to 0.95)

The one trial of 94 women comparing once daily with twice daily vaginal metronidazole did not show a difference in gestation of birth or low birthweight.

The addition of further data from the NICHD MFMU study has enlarged the meta-analysis of the impact of antibiotic treatment on neonatal sepsis and mortality. However, no significant decrease in neonatal sepsis was found.

Side-effects with the drug regimens included in the trials seem to be uncommon (although not reported in many of the studies), and they do not appear to result in large numbers of women having to stop treatment.

DISCUSSION

There is now a substantial body of evidence that associates bacterial vaginosis in pregnancy with a poor perinatal outcome, in particular an increased risk of preterm birth. This strong association between bacterial vaginosis and preterm birth has led many researchers and clinicians to believe that bacterial vaginosis may be the cause of preterm birth in these women.

The results of trials that treat bacterial vaginosis in pregnancy, however, are not encouraging. Previously, there was some suggestion, albeit based on small numbers of women, that antibiotic treatment on bacterial vaginosis in pregnancy can reduce the risk of preterm prelabour rupture of membranes. However, with the addition of three trials (Guaschino 2003; NICHD MFMU 2000; NICHD MFMU 2001), the association has weakened. There is some suggestion that identification and treatment of women with a previous preterm birth, who have asymptomatic bacterial vaginosis in pregnancy, may result in a decrease in the risk of subsequent low birthweight infant and preterm prelabour rupture of membranes. An earlier Cochrane review containing three trials of high risk women suggested an association between antibiotic treatment and a decreased risk of preterm birth, but with the addition of two recent trials (NICHD MFMU 2000; Odendaal 2002), no such association persists. (The relevant data on low birthweight and preterm prelabour rupture of membranes were not available for these recent studies, and the previous associations with low birth-weight and preterm prelabour rupture of membranes remain). The basis for enrolment in Odendaal's trial included both previous midtrimester miscarriage and preterm birth (Odendaal 2002).

The two recent trials of women with abnormal vaginal flora, ie intermediate flora or bacterial vaginosis (Lamont 2003; Ugwumadu 2003), showed significant association with preterm birth less than 37 weeks' gestation, which the authors postulate may be due to the

earlier gestation of treatment in both these studies (13 to 20 weeks (Lamont 2003) and 12 to 22 weeks, mean 15.6 (Ugwumadu 2003)). When analysed as a separate category, antibiotic treatment of abnormal flora resulted in a significant decrease in preterm birth. However, their inclusion in meta-analysis of all the trials has not made a substantial difference to the overall picture.

The results of the five trials (Kekki 1999; Kiss 2004; Lamont 2003; Morales 1994; NICHD MFMU 2000) in which women were treated before 20 weeks' gestation are encouraging, showing a significant association between treatment and preterm birth less than 37 weeks. However this finding needs to be further verified by future trials as there have been no head to head comparisons of early versus late treatment. The only trial large enough to stratify their results by early or later treatment failed to show any difference in effect when comparing earlier versus later treatment, although it could be argued that even in the early group, treatment was not started early enough.

Additional information on neonatal sepsis from the large NICHD MFMU trial has now been included in the analysis but provides no evidence of a reduction in neonatal sepsis.

Significant heterogeneity was found in several analyses - in the 'failure of cure' analysis this is probably due to differences in the timing of the test of cure and the method for determining test of cure. Also trials in this review have used several different methods of diagnosing bacterial vaginosis or abnormal genital flora (Amsel or clinical criteria, Gram stain criteria, and abnormal flora Nugent score 4-10. In the outcome 'preterm birth less than 37 weeks' heterogeneity occurred in the high-risk population subgroup, but not in the general population. This may be due to the variation in criteria for determining high-risk status. The heterogeneity seen in the oral antibiotics comparison of 'preterm birth less than 37 weeks' is similarly due to inclusion of a high risk study (Morales 1994).

Limitations of the trials

The trial protocols differ in a number of ways such as the method for diagnosing bacterial vaginosis, timing of screening, timing of treatment, and the period between screening and treatment. Most trials have tested treatment in the second trimester; some as late as 28 weeks' gestation. This may be too late to prevent ascending infection and may be one of the main reasons for the observed lack of a statistically significant effect on the preterm birth rates. The five studies in which women were treated before 20 weeks (Kekki 1999; Kiss 2004; Lamont 2003; Morales 1994; NICHD MFMU 2000 subgroup) showed a decrease in risk of preterm birth. Secondly, the efficacy of antibiotic treatment in long-term eradication of bacterial vaginosis is at best 80%. The subgroups of women in whom bacterial vaginosis was successfully eradicated, and those with recurring bacterial vaginosis, need to be identified and studied more closely in future trials.

Most trials have concentrated on the timing of birth and have made the assumption that the later in gestation a baby is born, the greater are its chances of disability-free survival. This may not be the case, however. Neonatal wellbeing and measures of maternal postpartum morbidity were each reported by two trials. However, the majority of outcomes we considered important for this review were not mentioned.

Since the first publication of the earlier Cochrane review in 1998 (Brocklehurst 1998), the number of women in this meta analysis has trebled, largely due to the inclusion of the NICHD MFMU 2000 and NICHD MFMU 2001 studies with 2132 women. This fourth review has increased the trial numbers by 586. Although there is still no evidence that screening and treating all women with bacterial vaginosis in the antenatal period will have a major impact on the consequences of preterm birth, there is now a suggestion that early treatment may be more effective.

AUTHORS' CONCLUSIONS

Implications for practice

The evidence to date does not suggest any benefit in screening and treating all pregnant women for asymptomatic bacterial vaginosis to prevent preterm birth. The lack of a significant effect despite large numbers of women in the included trials may be due to many differences within the trials regarding diagnosis, timing of treatment and antibiotic choice. In considering the implications for clinical practice it should be remembered, however, that women with symptomatic bacterial vaginosis were generally absent from these trials due to treatment of their symptoms with antibiotics. These women, especially those with recurrent or persistent bacterial vaginosis, may be at highest risk of associated adverse outcomes. Unfortunately, from studies to date we know almost nothing about the impact of these interventions on the health of the baby.

At the present time, there seems little justification for initiating a policy of screening for asymptomatic bacterial vaginosis in pregnancy. Any impact may be dependent upon early detection and treatment.

Implications for research

The consequences of preterm birth to the individuals concerned and the health services are of major importance. Any intervention with the potential to decrease the risk of mortality and morbidity associated with neonatal immaturity, therefore, needs prompt and appropriate evaluation so that any benefits may be maximised. The focus of current research is to identify those subgroups of pregnant women who are at highest risk for adverse sequelae of bacterial vaginosis. These subgroups include women with recurrent or persistent bacterial vaginosis. Individual susceptibility to preterm birth may also be increased by the presence of specific gene polymorphisms, producing a heightened inflammatory response to vaginal or intrauterine infection. In addition, recent findings suggest future studies may need to focus on earlier detection and treatment of bacterial vaginosis in the first trimester of pregnancy, or better still, preconception.

What then remains to be demonstrated is that a policy for screening and treatment for asymptomatic bacterial vaginosis in pregnancy can reduce substantive measures of morbidity associated with neonatal immaturity, and that this results in cost savings to families and the health services. Large trials are needed which can determine the effect of a screening programme on neonatal mortality and major measures of morbidity such as intracranial damage and chronic lung disease. For example, in the NICHD MFMU trial, to

reduce the incidence of neonatal morbidity by 25% (1.9% to 1.4%) with 90% power, significant at the 5% level, would require recruitment of at least 28,000 women.

If the detection and treatment of bacterial vaginosis can be shown to improve neonatal outcome, further trials will be necessary to determine the most effective antibiotic regimen.

[Note: The eleven citations in the awaiting assessment section of the review may alter the conclusions of the review once assessed.]

Acknowledgments

Professor Mary Hannah, Women's College Hospital, University of Toronto, Ontario, Canada: co-author on the first review.

Dr Rasiah Vigneswaran, deceased: co-author to 2002.

Jacqueline Parsons: co-author on the 2005 review.

Professor Caroline Crowther, Discipline of Obstetrics and Gynaecology, The University of Adelaide, for editorial advice.

SOURCES OF SUPPORT

Internal sources

- Women's and Children's Hospital, North Adelaide, Australia.

External sources

- Department of Health, UK.

CHARACTERISTICS OF STUDIES

Characteristics of included studies *[ordered by study ID]*

Duff 1991

Methods	"Adaptive randomization plan using a biased-can technique which balanced the groups after every 6 enrollees."
Participants	Women were screened for BV at 15-25 weeks' gestation. BV diagnosed on Gram stain (Nugents criteria). Exclusions: penicillin allergy, antimicrobial use within 2 weeks of enrolment, anticipated movement away from area, inability to speak English, diabetes, cervical cerclage, multiple pregnancy, hypertension on treatment, pregnancy-induced hypertension, fetal anomalies
Interventions	Amoxycillin 500 mg × 3/day for 14 days or matching placebo.
Outcomes	"Test-of-cure" 2 weeks after treatment complete, at 34-36 weeks and at admission in labour; preterm delivery; low birthweight; premature rupture of membranes; neonatal sepsis; maternal infection.
Notes	At randomization 54 antibiotic group vs 54 placebo. Loss to follow up - 7/54 (13%) in amoxycillin group, 9/54 (17%) in placebo group
<i>Risk of bias</i>	

Item	Authors' judgement	Description
Allocation concealment?	Yes	A - Adequate

Guaschino 2003

Methods	Phoned to randomization centre - randomization lists stratified for centre	
Participants	Pregnant women between 14-25 weeks with asymptomatic BV.	
Interventions	Intravaginal clindamycin 2% cream once daily for 7 days, vs no treatment	
Outcomes	Preterm delivery < 37 weeks. Low BW, PROM	
Notes	At randomization 49 antibiotic vs 51 no treatment. Not blinded. No placebo. 10.7% lost to follow up, 6 in each group	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	No	C - Inadequate

Hauth 1995

Methods	Blocked randomization scheme of 2:1 generated by investigational drug service	
Participants	Pregnant women at 22-24 weeks' gestation with history of previous preterm delivery or who weighed < 50 kg in current pregnancy. All women were screened for BV (diagnosed by Amsels criteria). Exclusions: allergies to metronidazole or erythromycin, uncertain gestational age, multiple pregnancy, prior vaginal bleeding, medical complications, any antibiotic use in the previous 4 weeks, co-infection with gonorrhoea, trichomonas or vaginal candida	
Interventions	Metronidazole 250 mg × 3/day for 7 days plus erythromycin base 333 mg × 3/day for 14 days or matching placebo. Treatment repeated if BV still present at "test-of-cure". Rx mean 27.6 weeks	
Outcomes	"Test-of-cure" 2 to 4 weeks after treatment; preterm delivery before 37 weeks.	
Notes	All women who were enrolled in the trial were treated with antibiotics/placebo at trial entry regardless of whether they had BV - this formed a post-randomization stratification. BV positive women - 176 antibiotic vs 87 placebo. Loss to follow up for the whole trial cohort - 7/176 (4%) in antibiotic group, 1/87 (1%) in placebo group. Data not provided for the subset with bacterial vaginosis	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear

Joesoef 1995

Methods	Random-number generator in balanced blocks of 6. Stratified by centre.	
Participants	Pregnant women screened at 14-26 weeks for BV (Nugents criteria).	

Exclusions: allergy to clindamycin, medical condition associated with preterm delivery (hypertension, multiple pregnancy, diabetes etc), previous tocolytic treatment, previous steroid treatment, antibiotics in 2 weeks before trial entry, age < 15 years, uterine or fetal abnormalities or incompetent cervix

Interventions	Clindamycin cream 2% - 5 g intravaginally at bedtime for 7 days or matching placebo. 43% enrolled @ less than 20 weeks	
Outcomes	“Test-of-cure” 2 weeks after completion of treatment and again after 34 weeks; preterm delivery < 37 and < 32 weeks; low birthweight (< 2500 g).	
Notes	At randomization 340 antibiotic vs 341 placebo. Loss to follow up - 64/745 (9%)	
Risk of bias		
Item	Authors’ judgement	Description
Allocation concealment?	Yes	A - Adequate

Kekki 1999

Methods	Block randomization within each centre (3 centres). Allocation in sealed envelopes. Double blinded	
Participants	Pregnant women with BV (screened at 10-17 weeks, using Spiegel’s criteria). Exclusions: multiple pregnancy, history of preterm birth, induced/spontaneous abortion, move to another city	
Interventions	2% vaginal clindamycin cream (single course) for 7 days or matching placebo for 7 days. Randomized @ 12-19 weeks	
Outcomes	“Test-of-cure” 1 week after treatment; spontaneous preterm delivery < 37 weeks’ gestation; peripartum infectious morbidity (postpartum endometritis, postpartum sepsis, caesarian section wound infection, episiotomy infection necessitating antibiotic treatment)	
Notes	At randomization 187 antibiotic vs 188 placebo. No dropouts, but 35 attended only 1 follow up visit. 21 (6%) given additional topical treatment for symptomatic BV. Intention-to-treat analysis	
Risk of bias		
Item	Authors’ judgement	Description
Allocation concealment?	Yes	A - Adequate

Kiss 2004

Methods	Computer-generated randomization list.	
Participants	Pregnant women at 15-19 weeks’ gestation all screened for BV (Nugents criteria) Exclusions: subjective complaints of vaginal infection, multiple pregnancy	
Interventions	2% vaginal clindamycin cream for 6 days, given 7-10 days after diagnosis. (12-19 weeks). No treatment for control group. Retreated if still present @ follow up	
Outcomes	Preterm birth < 37 weeks, intrauterine death, miscarriage, bw < 2500, < 2000, < 1500 and < 1000 g	
Notes	Not intention-to-treat. 274 excluded from analysis post randomization leaving 177 antibiotic vs 179 placebo. Lost to follow up 8 in BV group and 13 in controls	
Risk of bias		
Item	Authors’ judgement	Description

Allocation concealment?	Yes	A - Adequate
-------------------------	-----	--------------

Lamont 2003

Methods	Computerised block randomization (block size 10).
Participants	Asymptomatic pregnant women 13-20 weeks with BV or intermediate flora by Nugent's criteria. Excluded women with sensitivity to clindamycin; history of antibiotic-related colitis; inflammatory bowel disease or frequent periodic diarrhoea
Interventions	5 g of 2% clindamycin intravaginal cream (+ 100 mg) or placebo for 3 nights. In addition 7 extra days if vaginal swab still positive (BV/intermediate flora) at visit 2
Outcomes	Preterm birth < 37 weeks; low birthweight, very low birthweight, stillborn
Notes	Intent-to-treat analysis. 30 did not return for visit 2 in clindamycin group, and 11 in the placebo group, leaving 208 antibiotic vs 201 placebo

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Unclear	D - Not used

McDonald 1997

Methods	Random-number tables in balanced blocks of 16 for each centre
Participants	Pregnant women at 18 weeks' gestation with BV or Gardnerella vaginalis. Exclusions: multiple pregnancy, age < 17 years, in-vitro fertilisation, allergy to metronidazole, symptomatic BV requiring treatment, ruptured membranes, cervical cerclage, diabetes, placenta previa, antibiotic treatment for vaginitis within 2 weeks of trial entry, inability to attend before 28 weeks, language difficulties
Interventions	Metronidazole 400 mg × 2/day for 2 days at 24 weeks' gestation or matching placebo. If repeat swabs remained positive at 28 weeks' gestation a further course of treatment was given
Outcomes	Preterm birth < 37 weeks; preterm premature rupture of the membranes; stratified by previous history of preterm delivery.
Notes	The women included in this review were the subset of women with bacterial vaginosis, (56% of total trial cohort). Women with a heavy growth of Gardnerella but no bacterial vaginosis have not been included. Loss to follow up - 10/439 (2%) metronidazole group, 12/440 (3%) placebo group. Leaving BV positive randomized to 242 antibiotic vs 238 placebo Additional information supplied by investigator.

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Yes	A - Adequate

Morales 1994

Methods	Random-number tables.
Participants	Pregnant women with a previous preterm delivery who were screened for BV at 13-20 weeks (Amsels criteria).

Exclusions: trichomonas infection, medical complications, cocaine use, previous preterm delivery due to intrauterine infection or incompetent cervix, antibiotic use during 2 weeks prior to trial entry, lethal fetal abnormality, 2nd trimester bleeding, asymptomatic bacteriuria on initial screen

Interventions	Metronidazole 250 mg × 3/day for 7 days or matching vitamin C placebo	
Outcomes	Admission for preterm labour; preterm birth (< 34 and < 37 weeks); low birthweight (< 2500 g); preterm rupture of membranes.	
Notes	Not intention-to-treat analysis - women were excluded from the analysis if they failed to complete the assigned treatment - 6/94 women in total (6%). Loss to follow up - 5/94 in total (5%). Leaving 44 antibiotic vs 36 placebo	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	Yes	A - Adequate

NICHD MFMU 2000

Methods	Computer-generated randomization, with stratification according to clinical centre	
Participants	Pregnant women at 16-23 + 6 weeks with asymptomatic BV (not TV+) (screened at 8-22 + 6 weeks) gestation. Excluded: multifetal gestation; allergy to metronidazole; current abuse of ethanol; antibiotic treatment within previous 14 days; intention to receive antenatal care or deliver at location where no follow up possible; planned antibiotic treatment before delivery; current/planned Cx cerclage; preterm labour before screening; current/planned tocolytic treatment; fetal death/known life-threatening anomaly; medical illnesses requiring long-term/intermittent drug treatment: if received any antibiotics between screening and study treatment, if time between screening and randomization exceeded 8 weeks, or if tests for syphilis or chlamydia were positive	
Interventions	8 × 250 mg dose oral metronidazole or placebo plus repeat dose in 48 hours (@ 16-23 + 6 weeks' gestation). Second treatment at 24-30 weeks' gestation.	
Outcomes	"Test-of-cure" at least 14 days after initial visit and before second treatment; gestational age at delivery; birthweight; pPROM (at least 1 hr); clinical intra-amniotic infection; postpartum endometritis; neonatal sepsis; use of tocolytic drugs; visits and admissions to hospital; preterm labour	
Notes	Low recruitment response - only 29% BV+ women were enrolled. 10% did not return for follow up visit, leaving 953 antibiotic vs 966 placebo. Unpublished data on neonatal morbidity and admission to a neonatal unit were supplied by the authors	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	No	C - Inadequate

NICHD MFMU 2001

Methods	Computer-generated randomization, with stratification according to clinical centre, based on Trichomonas positive result	
Participants	Pregnant women at 16-23 + 6 weeks with positive culture for trichomonas vaginalis plus asymptomatic BV (screened at 8-22 + 6 weeks' gestation). Excluded: multifetal gestation; allergy to metronidazole; current abuse of ethanol; antibiotic treatment within previous 14 days; intention to receive antenatal care or deliver at location where no follow up possible; planned antibiotic treatment before delivery; current/planned Cx cerclage; preterm labour before screening; current/planned tocolytic treatment; fetal death/known life-threatening anomaly; medical illnesses requiring long-term/intermittent drug treatment: if received any	

	antibiotics between screening and study treatment, if time between screening and randomization exceeded 8 weeks, or if tests for syphilis or chlamydia were positive
Interventions	8 × 250 mg dose oral metronidazole or placebo plus repeat dose in 48 hours. Second treatment at 24-30 weeks gestation
Outcomes	Preterm delivery; birthweight; antibiotics prescribed after randomization; hospital admissions for preterm labour or PPROM; tocolysis; preterm rupture of membranes; clinical intra-amniotic infection; postpartum endometritis; suspected or confirmed neonatal sepsis
Notes	Parallel study to NICHD MFMU 2000 assessing Met vs placebo for those with positive trichomonas. Subgroup that had BV plus trichomonas analysed. 119 antibiotic vs 113 placebo

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Yes	A - Adequate

Odendaal 2002

Methods	Blocked randomization using computer, but not done separately for 2 groups
Participants	2 groups of women with BV (Spiegel's criteria): primigravidae at first antenatal visit, between 15 and 26 weeks' gestation; women with a previous preterm labour/midtrimester miscarriage. Exclusions: multiple pregnancy; known cervical incompetence
Interventions	Oral metronidazole 400 mg twice daily for 2 days and if still BV positive after 4 weeks, repeat treatment course, or placebo containing 100 mg vitamin C at matching times
Outcomes	"Test-of-cure" 4 weeks after; preterm delivery < 37, < 34, < 28 weeks' gestation; birthweight; intrauterine death; neonatal death; perinatal death; 5-minute Apgar score
Notes	Women with a history of taking antibiotics within the previous 2 weeks had enrolment postponed for 2 weeks. Lost to follow up participants not separated into treatment/placebo. Intention-to-treat analysis of 128 antibiotic vs 127 placebo

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Yes	A - Adequate

Porter 2001

Methods	Randomization method unknown.
Participants	Pregnant women with BV at 12 to 28 weeks' gestation (3 out of 4 Amsel criteria confirmed by Nugent's and Spiegel's criteria)
Interventions	Once daily vs twice daily vaginal metronidazole gel (0.75%) for 5 days (no placebo). Repeat treatment if positive at follow up
Outcomes	"Test-of-cure" at unknown time after treatment; gestation at delivery; birthweight; 1-min and 5-min Apgar scores; caesarean section rate; spontaneous rupture of membranes; intra-amniotic infection; endometritis; bladder infection
Notes	Study not yet completed. 186 out of 194 delivered at his point. No further publication of data

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear

Ugwumadu 2003

Methods	Computer-generated randomization. Allocation blinded until after data analysis	
Participants	Pregnant women (12-22 weeks) with asymptomatic intermediate flora (Nugent score 4-6) or BV (Nugent 7-10)	
Interventions	Oral clindamycin 300 mg or placebo twice daily for 5 days.	
Outcomes	Spontaneous preterm birth (> or = 24 to < 37 weeks and late miscarriage (> or = 13 weeks but < 24 weeks). Death in utero. "Test of cure" at 14 days post AB or placebo, NICU admission, BW < 2500, BW < 1500	
Notes	Intention-to-treat analysis. 9 women lost to follow up, leaving 244 antibiotic vs 241 placebo. PTB stratified by Nugent score 1-10, previous PTB, and race	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	Yes	A - Adequate

Vermeulen 1999

Methods	Blocks of 4 stratified by centre and by BV.	
Participants	Pregnant women with a history of spontaneous preterm birth in preceding pregnancy. Exclusions: multiple pregnancy, major fetal congenital anomalies, previous preterm birth associated with hypertension or preeclampsia, placental disorders, congenital uterine anomalies, maternal diseases or allergy to clindamycin	
Interventions	2% clindamycin vaginal cream or placebo daily for 7 days at 26 weeks and again at 32 weeks	
Outcomes	Spontaneous preterm delivery < 37 weeks; admission for threatened preterm labour; neonatal infectious morbidity; infectious morbidity associated with sepsis; pneumonia	
Notes	Treated all high-risk women with and without BV. Low sample size: needed 566 but enrolled 168. Only 11 BV positive women in antibiotic group vs 11 placebo. Intention-to-treat analysis.	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear

AB: antibiotic

BV: bacterial vaginosis

BW: birthweight

Cx: cervix

hr: hour

MET: metronidazole

min: minutes

NICU: neonatal intensive care unit

pPROM: preterm premature rupture of membranes

PROM: premature rupture of membranes

PTB: preterm birth

TV: Trichomonas vaginalis

vs: versus

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Andrews 2005	Women not pregnant at randomization and treatment plus women not specifically screened for bacterial vaginosis
Goldenberg 2006	Studied 3120 HIV+ and 600 HIV- women. No pregnancy outcomes for bacterial vaginosis positive women
Hawkinson 1966	Study conducted before diagnostic criteria for bacterial vaginosis were established
Hitti 2002	No pregnancy-outcome data.
Holst 1990	Not a randomized trial. Not an evaluation of an antibiotic regimen
Klebanoff 2004	Study of regression of asymptomatic BV. No pregnancy outcome data
Leitich 2003	Meta-analysis of existing studies.
McGregor 1994	This was a two phase observational trial (phase 1 - examination for BV and micro-organisms: phase 2 - treatment for infected women) and is not a randomized placebo-controlled trial
Neri 1993	Intervention agent yoghurt. Did not fulfil entry criteria for review
Paternoster 2004	Intervention not antibiotic.
Rosnes 2002	No evaluation of pregnancy outcome.
Shennan 2006	No outcomes for women with bacterial vaginosis.
Steyn 2003	Not an evaluation of an antibiotic regimen.
Thiagarajan 1998	No evaluation of pregnancy outcome.
Ugwumadu 1999	No usable data available, trial report in abstract form only
Yudin 2002	No evaluation of pregnancy outcome.
Yudin 2003	No evaluation of pregnancy outcome.

BV: bacterial vaginosis

DATA AND ANALYSES

Comparison 1

Any antibiotic versus placebo/no treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure of test of cure	10	4357	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.17 [0.15, 0.20]
2 Postpartum infection	2	618	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.67 [0.39, 1.17]
3 Perinatal death	3	2666	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.96 [0.53, 1.73]
4 Incidence of preterm prelabour rupture of membranes	4	2501	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.10 [0.74, 1.63]
4.1 General population	3	2499	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.10 [0.74, 1.63]
4.2 High-risk population	1	2	Peto Odds Ratio (Peto, Fixed, 95% CI)	Not estimable
5 Preterm birth < 37 weeks	12	5888	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.91 [0.78, 1.06]
5.1 General population	8	4291	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.06 [0.87, 1.28]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.2 High-risk population	5	703	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.78 [0.56, 1.08]
5.3 Intermediate flora and bacterial vaginosis	2	894	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.51 [0.32, 0.81]
6 Preterm birth < 34 weeks	4	851	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.22 [0.67, 2.19]
6.1 General population	2	628	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.95 [0.38, 2.37]
6.2 High-risk women	3	223	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.45 [0.67, 3.14]
7 Preterm birth < 32 weeks	4	3565	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.14 [0.76, 1.70]
7.1 General population	3	3080	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.08 [0.70, 1.68]
7.2 Intermediate flora and bacterial vaginosis	1	485	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.49 [0.53, 4.16]
8 Incidence of low birthweight	7	4107	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.95 [0.77, 1.17]
8.1 General population	4	3151	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.00 [0.79, 1.27]
8.2 High-risk women	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.33 [0.11, 0.93]
8.3 Intermediate flora and bacterial vaginosis	2	876	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.95 [0.59, 1.52]
9 Neonatal sepsis	3	2345	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.40 [0.45, 4.36]
10 Side-effects sufficient to stop treatment	3	1450	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.57 [0.95, 2.59]
11 Side-effects not sufficient to stop treatment	3	1340	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.33 [0.73, 2.42]
12 Severe neonatal morbidity	1	1917	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.96 [0.50, 1.84]
13 Admission to neonatal unit	2	2383	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.11 [0.87, 1.41]

Comparison 2

Oral antibiotics versus placebo/no treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure of test of cure	7	3244	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.15 [0.13, 0.17]
2 Postpartum uterine infection	1	243	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.69 [0.37, 19.30]
3 Perinatal death	3	2656	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.94 [0.52, 1.70]
4 Incidence of preterm prelabour rupture of membranes	3	2479	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.80 [0.54, 1.19]
5 Preterm birth < 37 weeks	8	4069	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.90 [0.75, 1.08]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6 Preterm birth < 34 weeks	3	819	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.30 [0.72, 2.35]
7 Preterm birth < 32 weeks	3	2884	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.98 [0.61, 1.55]
8 Incidence of low birthweight	4	2926	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.89 [0.70, 1.13]
9 Neonatal sepsis	2	2323	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.40 [0.45, 4.36]
10 Side-effects sufficient to stop treatment	2	965	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.30 [0.69, 2.47]
11 Side-effects not sufficient to stop treatment	2	965	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.47 [0.73, 2.99]
12 Severe neonatal morbidity	1	1917	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.96 [0.50, 1.84]
13 Admission to a neonatal unit	2	2383	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.11 [0.87, 1.41]

Comparison 3

Vaginal antibiotics versus placebo/no treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure of test of cure	3	1113	Peto Odds Ratio (Peto, Fixed, 95% CI)	270.27 [0.21, 0.35]
2 Postpartum uterine infection	1	375	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.60 [0.34, 1.07]
3 Perinatal death	1	409	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.35 [0.05, 2.52]
4 Incidence of preterm prelabour rupture of membranes	1	100	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.52 [0.69, 9.25]
5 Preterm birth < 37 weeks	5	1921	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.88 [0.64, 1.21]
6 Preterm birth < 34 weeks	1	22	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.0 [0.06, 17.12]
7 Preterm birth < 32 weeks	1	681	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.79 [0.81, 3.98]
8 Incidence of low birthweight	3	1181	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.14 [0.75, 1.74]
9 Neonatal sepsis	2	431	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.17 [0.58, 2.39]
10 Side-effects not sufficient to stop treatment	1	375	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.01 [0.32, 3.17]

Comparison 4

Previous preterm delivery: antibiotics versus placebo/no treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure of test of cure	2	201	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.11 [0.06, 0.19]
2 Postpartum uterine infection	1	15	Peto Odds Ratio (Peto, Fixed, 95% CI)	Not estimable
3 Perinatal death	2	155	Peto Odds Ratio (Peto, Fixed, 95% CI)	3.64 [0.86, 15.45]
4 Incidence of preterm prelabour rupture of membranes	2	114	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.14 [0.05, 0.38]
5 Preterm delivery < 37 weeks	5	622	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.83 [0.59, 1.17]
6 Preterm delivery < 34 weeks	4	257	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.21 [0.59, 2.49]
7 Preterm delivery < 32 weeks	1	34	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.49 [0.05, 5.08]
8 Incidence of low birthweight	2	114	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.31 [0.13, 0.75]
9 Neonatal sepsis	2	52	Peto Odds Ratio (Peto, Fixed, 95% CI)	Not estimable

Comparison 5

Single daily dose versus double daily dose vaginal antibiotic

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Postpartum uterine infection	1	94	Peto Odds Ratio (Peto, Fixed, 95% CI)	3.08 [0.42, 22.59]
2 Preterm delivery < 37 weeks	1	94	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.40 [0.11, 1.39]
3 Incidence of low birthweight	1	94	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.25 [0.49, 3.20]

Comparison 6

Intermediate flora/bacterial vaginosis: antibiotics versus placebo/no treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure of test of cure	1	462	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.04 [0.03, 0.05]
2 Perinatal death	2	894	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.50 [0.10, 2.48]
3 Preterm birth < 37 weeks	2	894	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.51 [0.32, 0.81]
4 Preterm birth < 32 weeks	1	485	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.49 [0.53, 4.16]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5 Incidence of low birthweight	2	876	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.95 [0.59, 1.52]
6 Late miscarriage	1	485	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.25 [0.08, 0.79]
7 Side-effects sufficient to stop or change treatment	1	485	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.11 [0.94, 4.71]
8 Admission to neonatal unit	1	466	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.73 [0.39, 1.39]

Comparison 7

Clindamycin (oral or vaginal) versus placebo/no treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure of test of cure	4	1575	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.14 [0.12, 0.18]
2 Postpartum uterine infection	1	375	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.60 [0.34, 1.07]
3 Perinatal death	2	894	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.50 [0.10, 2.48]
4 Incidence of preterm prelabour rupture of membranes	1	100	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.52 [0.69, 9.25]
5 Preterm birth < 37 weeks	6	2406	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.80 [0.60, 1.05]
6 Preterm birth < 34 weeks	1	22	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.0 [0.06, 17.12]
7 Preterm birth < 32 weeks	2	1166	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.67 [0.89, 3.14]
8 Incidence of low birthweight	4	1648	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.03 [0.73, 1.45]
9 Neonatal sepsis	2	431	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.17 [0.58, 2.39]
10 Side-effects sufficient to stop or change treatment	1	485	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.11 [0.94, 4.71]
11 Late miscarriage	1	485	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.25 [0.08, 0.79]
12 Admission to neonatal unit	1	466	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.73 [0.39, 1.39]

Comparison 8

Treatment at less than 20 weeks' gestation

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure of test of cure	2	442	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.21 [0.14, 0.30]
2 Postpartum uterine infection	1	375	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.60 [0.34, 1.07]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3 Incidence of preterm prelabour rupture of membranes	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.14 [0.04, 0.44]
4 Preterm birth less than 37 weeks	5	2287	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.72 [0.55, 0.95]
4.1 General population	3	1798	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.87 [0.64, 1.19]
4.2 High-risk population	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.29 [0.11, 0.76]
4.3 Intermediate flora and bacterial vaginosis	1	409	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.40 [0.19, 0.88]
5 Preterm birth less than 34 weeks' gestation	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.39 [0.07, 2.07]
5.1 High-risk population	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.39 [0.07, 2.07]
6 Incidence of low birthweight	2	489	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.79 [0.44, 1.41]
6.1 High-risk population	1	80	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.33 [0.11, 0.93]
6.2 Intermediate flora and bacterial vaginosis	1	409	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.17 [0.58, 2.39]
7 Side-effects not sufficient to stop treatment	1	375	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.01 [0.32, 3.17]
7.1 General population	1	375	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.01 [0.32, 3.17]

FEEDBACK

Klebanoff, October 2005

Summary

I have a couple of minor technical corrections. First, the NICHD trial (NICHD MFMU 2000) randomized women from 16 to 24 weeks, not from 18 to 24 weeks. In fact, these women were randomized not much later than those in Ugwumadu 2003.

Second, women with bacterial vaginosis plus *Trichomonas* were not eligible for the NICHD study included in this review. However, they were randomized into a parallel NICHD *Trichomonas* study [1]. In that study, we presented results separately for women who had *Trichomonas* only and women who had *Trichomonas* plus bacterial vaginosis. Since many other bacterial vaginosis trials did not screen for *Trichomonas*, and therefore probably randomized some women who had both, there is no reason to exclude such women recruited to our second study from your review.

Finally, our original draft of the paper for NICHD MFMU 2000 included data on neonatal mortality and morbidity. This table was removed at the request of the NEJM Editor. If you wish, I can investigate whether we can provide you with this additional data.

Reference [1] Klebanoff MA, Carey JC, Hauth JC, Hillier SL, Nugent RP, Thom EA, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic *Trichomonas vaginalis* infection. *N Engl J Med*. 2001;345:487-93.

(Summary of comments from Mark Klebanoff, October 2005)

Reply

Thank you very much for your comments. We have addressed each of your points in this update as follows:

1. the information about NICHD MFMU 2000 is now correct, women were enrolled between 16 to 24 weeks;
2. we have included the published data from the NICHD Trichomonas study (NICHD MFMU 2001);
3. data from NICHD MFMU 2000 on neonatal mortality and morbidity supplied by the authors have been included.

(Summary of response from Helen McDonald, November 2006)

Contributors

Mark Klebanoff

HISTORY

Protocol first published: Issue 3, 1997

Review first published: Issue 4, 1998

Date	Event	Description
29 April 2008	Amended	Converted to new review format.
29 April 2008	Amended	Corrected data input error for Morales 1994 for comparison 08.04.
13 November 2006	Feedback has been incorporated	Response to feedback from Mark Klebanoff added.
25 September 2006	New search has been performed	(1) Search updated May 2006. (2) Addition of co-author Dr Adrienne Gordon. (3) Addition of extra neonatal data in NICHD MFMU 2000 study. (4) Addition of three new studies (NICHD MFMU 2001 with parallel data to NICHD MFMU 2000; Lamont 2003; Kiss 2004). (5) Analysis of clindamycin trials. (6) Analysis of abnormal vaginal flora trials (recruited on the basis of Nugent score 4-10). (7) Analysis of treatment at less than 20 weeks' gestation.
25 September 2006	New citation required and conclusions have changed	Substantive amendment

WHAT'S NEW

Last assessed as up-to-date: 24 September 2006.

Date	Event	Description
18 November 2010	Amended	Search updated. Eleven new reports added to Studies awaiting classification.

References to studies included in this review

- Duff 1991 {published data only} . Duff P, Lee ML, Hillier SL, Herd LM, Krohn MA, Eschenbach DA. Amoxicillin treatment of bacterial vaginosis during pregnancy. *Obstetrics & Gynecology*. 1991; 77:431–5. [PubMed: 1992412]
- Guaschino 2003 {published data only} . Guaschino S, Grimaldi E, de Seta F, Mangino F. Bacterial vaginosis and preterm delivery. *Acta Obstetrica et Gynecologica Scandinavica Supplement*. 1997; 76(167):35.*Guaschino S, Ricci E, Franchi M, Frate GD, Tibaldi C, Santo DD, et al. Treatment of asymptomatic bacterial vaginosis to prevent pre-term delivery: a randomised trial. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2003; 110:149–52. [PubMed: 12969574]
- Hauth 1995 {published data only} . Hauth J, Goldenberg R, Andrews W, Copper R, Schmid T. Efficacy of metronidazole plus erythromycin to decrease bacterial vaginosis and other markers of altered vaginal flora [abstract]. *American Journal of Obstetrics and Gynecology*. 1993; 168:421.Hauth J, Goldenberg R, Andrews W, Dubard M, Copper R. Mid trimester treatment with metronidazole plus erythromycin reduces preterm delivery only in women with bacterial vaginosis. *American Journal of Obstetrics and Gynecology*. 1995; 172:253.Hauth J, Goldenberg R, Andrews W, Dubard M, Copper R. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. *Obstetrical & Gynecological Survey*. 1996; 51(6):329–30.Hauth JC, Goldenberg RL, Andrews WW, Copper RL, DuBard MB, Schmid T. The effect of mid-trimester metronidazole plus erythromycin on bacterial vaginosis and other markers of altered vaginal flora [abstract]. *American Journal of Obstetrics and Gynecology*. 1995; 172:303.*Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. *New England Journal of Medicine*. 1995; 333:1732–6. [PubMed: 7491136]
- Joesoef 1995 {published data only} . Joesoef MR, Hillier SL, Wiknjosastro G, Sumampouw H, Linnan M, Norojono W, et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. *American Journal of Obstetrics and Gynecology*. 1995; 173:1527–31. [PubMed: 7503196]
- Kekki 1999 {published data only} . Kekki M, Kurki T, Kurkinen-Raty M, Pelkonen J, Paavonen J. Recurrent bacterial vaginosis in pregnancy predisposes to infectious morbidity: a double-blind, placebo-controlled multicenter intervention trial with vaginal clindamycin. *International Journal of Gynecology & Obstetrics*. 1999; 67(Suppl 2):S42.Kekki M, Kurki T, Paavonen J, Rutanen E-M. Insulin-like growth factor binding protein-1 in cervix as a marker of infectious complications in pregnant women with bacterial vaginosis. *Lancet*. 1999; 353:1494. [PubMed: 10232319] Kekki M, Kurki T, Pelkonen J, Kurkinen-Raty M, Cacciatore B, Paavonen J. Bacterial vaginosis in pregnancy is associated with infectious morbidity - a randomized placebo-controlled intervention trial with vaginal clindamycin. *Acta Obstetrica et Gynecologica Scandinavica Supplement*. 1996; 76(167):28.Kekki M, Kurki T, Pelkonen J, Kurkinen-Raty M, Cacciatore B, Paavonen J. Vaginal clindamycin in preventing preterm birth and peripartum infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. *Obstetrics & Gynecology*. 2001; 97(5 Pt 1):643–8. [PubMed: 11339909] Kekki, M.; Kurki, T.; Pelkonen, J.; Kurkinen-Raty, M.; Cacciatore, B.; Paavonen, J. Vaginal clindamycin is ineffective in preventing preterm birth and peripartum infections in a low risk population with bacterial vaginosis: a double-blind placebo-controlled multicenter trial. XVI FIGO World Congress of Obstetrics and Gynecology (Book 3); Washington DC, USA. 2000 September 3-8; 2000. Kekki M, Kurki T, Polkonen J, Cacciatore B, Paavonen J. Bacterial vaginosis in pregnancy is associated with infectious morbidity - a randomized placebo-controlled trial with vaginal clindamycin. *Acta Obstetrica et Gynecologica Scandinavica*. 1996; 75:87.*Kurkinen-Raty M, Vuopala S, Koskela

- M, Kekki M, Kurki T, Paavonen J, et al. A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. *BJOG: an international journal of obstetrics and gynaecology*. 2000; 107:1427–32. [PubMed: 11117774]
- Kiss 2004 {published data only} . Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. *BMJ*. 2004; 329:371. [PubMed: 15294856]
- Lamont 2003 {published data only} . Lamont, R.; Adinkra, P.; Mason, M. The use of clindamycin intravaginal cream in the treatment of abnormal genital tract flora- safety and efficacy. Proceedings of the 4th International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists; Cape Town, South Africa. 1999 October 3-6; 1999. p. 82
Lamont R, Morgan D, Sheehan M, Duncan S, Mandal D. The outcome of pregnancy following the use of clindamycin intravaginal cream for the treatment of abnormal colonization: a prospective, randomised, double-blind, placebo-controlled multicenter study. *International Journal of Gynecology & Obstetrics*. 1999; 67(Suppl 2):S42.
Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. *Obstetrics & Gynecology*. 2003; 101(3):516–22. [PubMed: 12636956]
Lamont RF, Jones BM, Mandal D, Hay PE, Sheehan M. The efficacy of vaginal clindamycin for the treatment of abnormal genital tract flora in pregnancy. *Infectious Diseases in Obstetrics and Gynecology*. 2003; 11(4):181–9. [PubMed: 15108863]
Lamont RF, Sheehan M, Morgan DJ, Mandal D, Duncan SLB. Safety and efficacy of clindamycin intravaginal cream for the treatment of bacterial vaginosis in pregnancy: a randomized, double-blind placebo-controlled multicenter study. *International Journal of Gynecology & Obstetrics*. 1999; 67(Suppl 2):S45.
Mason, MR.; Lamont, RF.; Adinkra, PE. Pregnancy outcome following treatment of abnormal genital tract flora with a three day course of 2% clindamycin. Proceedings of the 4th International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists; Cape Town, South Africa. 1999 October 3-6; 1999. p. 82-3.
Rosenstein I, Morgan D, Sheehan M, Lamont R, Taylor-Robinson D. Effect of topical clindamycin on bacterial vaginosis and outcome of pregnancy. *International Journal of Gynecology & Obstetrics*. 1999; 67(Suppl 2):S43.
Rosenstein IJ, Morgan DJ, Lamont RF, Sheehan M, Dore CJ, Hay PE, et al. Effect of intravaginal clindamycin cream on pregnancy outcome and on abnormal vaginal microbial flora of pregnant women. *Infectious Diseases in Obstetrics and Gynecology*. 2000; 8:158–65. [PubMed: 10968599]
*Taylor-Robinson D, Morgan DJ, Sheehan M, Rosenstein IJ, Lamont RF. Relation between Gram-stain and clinical criteria for diagnosing bacterial vaginosis with special reference to Gram grade II evaluation. *International Journal of STD and AIDS*. 2003; 14:6–10. [PubMed: 12590785]
- McDonald 1997 {published and unpublished data} . McDonald HM, O'Loughlin JA, Vigneswaran R, Jolley PT, Harvey JA, Bof A, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (*Gardnerella vaginalis*): a randomised, placebo controlled trial. *British Journal of Obstetrics and Gynaecology*. 1997; 104:1391–7. [PubMed: 9422018]
McDonald HM, O'Loughlin JA, Vigneswaran R, Jolley PT, McDonald PJ. Bacterial vaginosis in pregnancy and efficacy of short-course oral metronidazole treatment: a randomised controlled trial. *International Journal of Gynecology & Obstetrics*. 1995; 49:225.
McDonald HM, O'Loughlin JA, Vigneswaran R, Jolley PT, McDonald PJ. Bacterial vaginosis in pregnancy and efficacy of short-course oral metronidazole treatment: a randomized controlled trial. *Obstetrics & Gynecology*. 1994; 84:343–8. [PubMed: 8058228]
*Vigneswaran R, O'Loughlin J, McDonald H, McDonald P, Jolley P, Harvey J, et al. Metronidazole treatment of bacterial vaginosis in pregnancy, and effect on preterm birth. *Prenatal and Neonatal Medicine*. 1996; 1(Suppl 1):160.
- Morales 1994 {published data only} . Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. *American Journal of Obstetrics and Gynecology*. 1994; 171:345–9. [PubMed: 8059811]
*Morales WJ, Schorr SJ, Albritton J. Effect of metronidazole in patients with history of preterm birth and bacterial vaginosis: a placebo control double blind study [abstract]. *American Journal of Obstetrics and Gynecology*. 1993; 168:377.
- NICHD MFMU 2000 {published data only} . Carey J, Klebanoff M, Hauth J, Hillier S, Thom E, Ernest J, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. *New England Journal of Medicine*. 2000; 342:534–40. [PubMed: 10684911]
Goldenberg RL, Klebanoff M, Carey JC, MacPherson C. Metronidazole treatment of women

with a positive fetal fibronectin test result. *American Journal of Obstetrics and Gynecology*. 2001; 185:485–6. [PubMed: 11518914] Hauth J. Response of the three components of a vaginal Gram stain score to metronidazole treatment and in relation to preterm birth. *American Journal of Obstetrics and Gynecology*. 2000; 182(1 Pt 2):S56. Hauth J, Cliver S, Hodgkins P, Andrews W, Schwebke J, Hook E, et al. Mid-trimester metronidazole and azithromycin did not prevent preterm birth in women at increased risk: a double blind trial. *American Journal of Obstetrics and Gynecology*. 2001; 185(6):S86. Klebanoff M, Carey J. Metronidazole did not prevent preterm birth in asymptomatic women with bacterial vaginosis. *American Journal of Obstetrics and Gynecology*. 1999; 180(1 Pt 2):2. *Sheffield J. The effect of bacterial vaginosis treatment on the acquisition of other symptomatic sexually transmitted diseases during pregnancy [abstract]. *American Journal of Obstetrics and Gynecology*. 2001; 184(1 Pt 2):S83.

NICHD MFMU 2001 {published data only} . Klebanoff M, Carey C, Hauth JC, Hillier SL, Nugent RP, National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic trichomonas vaginalis infection. *New England Journal of Medicine*. 2001; 345:487–93. [PubMed: 11519502]

Odendaal 2002 {published data only} . Odendaal H, Popov I, Schoeman J, Smith M, Grove D. Preterm labour - is bacterial vaginosis involved? *South African Medical Journal*. 2002; 92(3): 231–4. [PubMed: 12040953]

Porter 2001 {published data only} . Porter K, Rambo D, Jazayeri A, Jazayeri M, Prien S. Prospective randomized trial of once versus twice a day metronidazole-vaginal in obstetrical population identified with bacterial vaginosis. *American Journal of Obstetrics and Gynecology*. 2001; 184(1 Pt 2):S166.

Ugwumadu 2003 {published data only} . Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. *Lancet*. 2003; 361:983–8. [PubMed: 12660054] Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. *Obstetrical & Gynecological Survey*. 2003; 58(9):566–7. Ugwumadu A, Manyonda I, Reid F, Hay P. Oral clindamycin for asymptomatic abnormal vaginal flora early in the second trimester of pregnancy reduces late miscarriage and spontaneous preterm birth [abstract]. *BJOG: an international journal of obstetrics and gynaecology*. 2003; 110:447. *Ugwumadu A, Reid F, Hay P, Manyonda I. Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin. *Obstetrics & Gynecology*. 2004; 104(1):114–9. [PubMed: 15229009]

Vermeulen 1999 {published data only} . Mason MR, Adinkra PE, Lamont RF. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial [letter]. *BJOG: an international journal of obstetrics and gynaecology*. 2000; 107(2):295–6. [PubMed: 10688520] Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. *British Journal of Obstetrics and Gynaecology*. 1999; 106:652–7. [PubMed: 10428520] *Vermeulen GM, van Zwet AA, Bruinse HW. Changes in the vaginal flora after two percent clindamycin vaginal cream in women at high risk of spontaneous preterm birth. *BJOG: an international journal of obstetrics and gynaecology*. 2001; 108:697–700. [PubMed: 11467693]

References to studies excluded from this review

Andrews 2005 {published data only} . Andrews WW, Goldenberg RL, Hauth JC, Cliver SP, Copper R, Conner M. Interconceptional antibiotics to prevent spontaneous preterm birth: a randomized clinical trial. *American Journal of Obstetrics and Gynecology*. 2006; 194:617–23. [PubMed: 16522388]

Goldenberg 2006 {published data only} . Goldenberg RL, Mwatha A, Read J, Adeniyi-Jones S, Sinkala M, Msmanga G, et al. The HPTN 024 study: the efficacy of antibiotics to prevent

- chorioamnionitis and preterm birth. *American Journal of Obstetrics and Gynecology*. 2006; 194(3):650–61. [PubMed: 16522393]
- Hawkinson 1966 {published data only} . Hawkinson J, Schulman H. Prematurity associated with cervicitis and vaginitis during pregnancy. *American Journal of Obstetrics and Gynecology*. 1966; 94:898–902. [PubMed: 5325806]
- Hitti 2002 {published data only} . Hitti J, Kullberg J, Lee Z, Culhane J, Lawler R, Hogan V, et al. Vaginal inflammation and secretory leukocyte protease inhibitor among women with bacterial vaginosis in early pregnancy: response to antibiotic treatment. *Infectious Diseases in Obstetrics and Gynecology*. 2002; 10(Suppl 1):S19.
- Holst 1990 {published data only} . Holst E, Brandberg A. Treatment of bacterial vaginosis in pregnancy with a lactate gel. *Scandinavian Journal of Infectious Diseases*. 1990; 22:625–6. [PubMed: 2259873]
- Klebanoff 2004 {published data only} . Klebanoff M, Hauth J, MacPherson CA, Carey J, Heine R, Wapner R, et al. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. *American Journal of Obstetrics and Gynecology*. 2004; 190:363–70. [PubMed: 14981375]
- Leitich 2003 {published data only} . Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. *American Journal of Obstetrics and Gynecology*. 2003; 189(1):139–47. [PubMed: 12861153]
- McGregor 1994 {published data only} . McGregor JA, French JI, Jones W, Milligan K, McKinney PJ, Patterson E, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. *American Journal of Obstetrics and Gynecology*. 1994; 170:1048–60. [PubMed: 8166188]
- Neri 1993 {published data only} . Neri A, Sabah G, Samra Z. Bacterial vaginosis in pregnancy treated with yoghurt. *Acta Obstetrica et Gynecologica Scandinavica*. 1993; 72:17–9. [PubMed: 8382424]
- Paternoster 2004 {published data only} . Paternoster DM, Tudor L, Milani M, Maggino T, Ambrosini A. Efficacy of an acidic vaginal gel on vaginal pH and interleukin-6 levels in low-risk pregnant women: a double-blind, randomized placebo-controlled trial. *Journal of Maternal-Fetal & Neonatal Medicine*. 2004; 15(3):198–201. [PubMed: 15280147]
- Rosnes 2002 {published data only} . Rosnes J, NICHD MFMU Network. Does vaginal pH or gram stain score alter the likelihood of successful metronidazole treatment of bacterial vaginosis (bv) or trichomonas vaginalis (tv) during pregnancy [abstract]. *American Journal of Obstetrics and Gynecology*. 2002; 187(6 Pt 2):S228.
- Shennan 2006 {published data only} . Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, Jones G, et al. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMETS study. *BJOG: an international journal of obstetrics and gynaecology*. 2006; 113(1):65–74. [PubMed: 16398774]
- Steyn 2003 {published data only} . Steyn PS, Odendaal HJ, Schoeman J, Stander C, Fanie N, Grove D. A randomised, double-blind placebo-controlled trial of ascorbic acid supplementation for the prevention of preterm labour. *Journal of Obstetrics and Gynaecology*. 2003; 23(2):150–5. [PubMed: 12745558]
- Thiagarajan 1998 {published data only} . Thiagarajan M. Evaluation of the use of yogurt in treating bacterial vaginosis in pregnancy [abstract]. *Journal of Clinical Epidemiology*. 1998; 51(Suppl 1):22S.
- Ugwumadu 1999 {published data only} . Ugwumadu A, Manyonda I, Hay PE. The natural history of bacterial vaginosis in pregnancy: results from a randomized, placebo-controlled and double-blind trial of systemic clindamycin at 12–18 weeks gestation. *International Journal of Gynecology and Obstetrics*. 1999; 67(Suppl 2):S43.
- Yudin 2002 {published data only} . Yudin MH, Landers DV, Hillier SL. Cytokine profiles in response to bacterial vaginosis in pregnancy before and after treatment with oral or vaginal metronidazole. *Infectious Diseases in Obstetrics and Gynecology*. 2002; 10(Suppl 1):S18.
- Yudin 2003 {published data only} . Yudin MH, Landers DV, Meyn L, Hillier SL. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis

during pregnancy: a randomized trial. *Obstetrics & Gynecology*. 2003; 102(3):527–34. [PubMed: 12962937]

References to studies awaiting assessment

- Darwish 2007 {published data only} . Darwish A, Elnshar EM, Hamadeh SM, Makarem MH. Treatment options for bacterial vaginosis in patients at high risk of preterm labor and premature rupture of membranes. *Journal of Obstetrics and Gynaecology Research*. 2007; 33(6):781–7. [PubMed: 18001442]
- Giuffrida 2006 {published data only} . Giuffrida G, Mangiacasale A. Bacterial vaginosis in pregnancy: treatment with peroxen vs vaginal clindamycin [Vaginosi batteriche in gravidanza: trattamento con peroxen vs clindamicina intravaginale.]. *Giornale Italiano di Ostetricia e Ginecologia*. 2006; 28(12):539–43.
- Kurtzman 2008 {published data only} . Kurtzman J, Chandiramani M, Briley A, Poston L, Shennan A. Quantitative fetal fibronectin screening at 24 weeks substantially discriminates the risk of recurrent preterm delivery in asymptomatic patients with prior preterm birth. *American Journal of Obstetrics and Gynecology*. 2008; 199(6 Suppl 1):S10.
- Larsson 2006 {published data only} . Larsson PG, Fahraeus L, Carlsson B, Jakobsson T, Forsum U, the premature study group of the southeast health care region of Sweden. Late miscarriage and preterm birth after treatment with clindamycin: a randomised consent design study according to Zelen. *BJOG: an international journal of obstetrics and gynaecology*. 2006; 113(6):629–37. [PubMed: 16709205]
- McDonald 1996 {published data only} . McDonald HM, O'Loughlin JA, Vigneswaran R, McDonald PJ, Jolley PT, Pharm B, et al. Metronidazole treatment of bacterial vaginosis in pregnancy, and preterm birth: a randomized, placebo-controlled trial. *Infectious Diseases in Obstetrics and Gynecology*. 1996; 4:49.
- Mitchell 2009 {published data only} . Mitchell C, Balkus J, Agnew K, Lawler R, Hitti J. Changes in the vaginal microenvironment with metronidazole treatment for bacterial vaginosis in early pregnancy. *Journal of Women's Health*. 2009; 18(11):1817–24.
- Mitchell 2009a {published data only} . Mitchell CM, Hitti JE, Agnew KJ, Fredricks DN. Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria. *BMC Infectious Diseases*. 2009; 9:89. [PubMed: 19515236]
- Schoeman 2005 {published data only} . Schoeman J, Steyn PS, Odendaal HJ, Grove D. Bacterial vaginosis diagnosed at the first antenatal visit better predicts preterm labour than diagnosis later in pregnancy. *Journal of Obstetrics and Gynaecology*. 2005; 25(8):751–3. [PubMed: 16368577]
- Subtil 2008 {published data only} . Subtil, D. [accessed 9 April 2008] Prevention of very preterm delivery by testing for and treatment of bacterial vaginosis. *ClinicalTrials.gov*. <http://clinicaltrials.gov/http://clinicaltrials.gov/>
- Thompson 2002 {published data only} . Thompson C. Taken before their time. *Nursing Times*. 2002; 98(3):29.
- Ugwumadu 2006 {published data only} . Ugwumadu A, Reid F, Hay P, Manyonda I, Jeffrey I. Oral clindamycin and histologic chorioamnionitis in women with abnormal vaginal flora. *Obstetrics & Gynecology*. 2006; 107(4):863–8. [PubMed: 16582124]

Additional references

- Amsel 1983 . Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. *American Journal of Medicine*. 1983; 74:14–22. [PubMed: 6600371]
- Annells 2004 . Annells MF, Hart PH, Mullighan CG, Heatley SL, Robinson JS, Bardy P, et al. Interleukins-1, -4, -6, -10, tumour necrosis factor, transforming growth factor-B, FAS, and mannose-binding protein C gene polymorphisms in Australian women: Risk of preterm birth. *American Journal of Obstetrics and Gynecology*. 2004; 191:2056–67. [PubMed: 15592292]
- Annells 2005 . Annells MF, Hart PH, Mullighan CG, Heatley SL, Robinson JS, McDonald HM. Polymorphisms in immunoregulatory genes and the risk of histologic chorioamnionitis in

- Caucasoid women: a case control study. *BMC Pregnancy and Childbirth*. 2005; 5(1):4. [PubMed: 15723707]
- Burtin 1995 . Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. *American Journal of Obstetrics and Gynecology*. 1995; 172:525–9. [PubMed: 7856680]
- Fischbach 1993 . Fischbach F, Petersen EE, Weissenbacher ER, Martius J, Hosmann J, Mayer H. Efficacy of clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis. *Obstetrics & Gynecology*. 1993; 82:405–10. [PubMed: 8355942]
- Hay 1994 . Hay PE, Morgan DJ, Ison CA, Bhide SA, Romney M, McKenzie P, et al. A longitudinal study of bacterial vaginosis during pregnancy. *British Journal of Obstetrics and Gynaecology*. 1994; 101:1048–53. [PubMed: 7826957]
- Hay 1994a . Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. *BMJ*. 1994; 308:295–8. [PubMed: 8124116]
- Hillier 1993 . Hillier SL, Krohn MA, Rabe LK, Klebanoff SJ, Eschenbach DA. The normal vaginal flora, H₂O₂-producing lactobacilli and bacterial vaginosis in pregnant women. *Clinical Infectious Diseases*. 1993; 16(Suppl 4):S273–S281. [PubMed: 8324131]
- Hillier 1995 . Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. *New England Journal of Medicine*. 1995; 333:1737–42. [PubMed: 7491137]
- Kurki 1992 . Kurki T, Sivonen A, Renkonen O-V, Savia E, Ylikorkala O. Bacterial vaginosis in early pregnancy and pregnancy outcome. *Obstetrics & Gynecology*. 1992; 80:173–7. [PubMed: 1635726]
- Lamont 1993 . Lamont, RF.; Fisk, NM. The role of infection in the pathogenesis of preterm labour. In: Studd, JWW., editor. *Progress in obstetrics and gynaecology*. Vol. Vol. 10. Churchill Livingstone; London: 1993. p. 135-58.
- McDonald 1994 . McDonald HM, O'Loughlin JA, Vigneswaran R, Jolley PT, McDonald PJ. Bacterial vaginosis in pregnancy and efficacy of short course oral metronidazole treatment: a randomized controlled trial. *Obstetrics & Gynecology*. 1994; 84:343–8. [PubMed: 8058228]
- McGregor 1990 . McGregor JA, French JI, Richter R, Franco-Buff A, Johnson A, Hillier S, et al. Antenatal microbiological maternal risk factors associated with prematurity. *American Journal of Obstetrics and Gynecology*. 1990; 163:1465–73. [PubMed: 2240089]
- Nugent 1991 . Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. *Journal of Clinical Microbiology*. 1991; 29:297–301. [PubMed: 1706728]
- RevMan 2003 . The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. The Cochrane Collaboration; Oxford, England: 2003.
- Simhan 2003 . Simhan HN, Krohn MA, Roberts JM, Zeevi A, Caritis SN. Interleukin-6 promoter -174 polymorphism and spontaneous preterm birth. *American Journal of Obstetrics and Gynecology*. 2003; 189(4):915–8. [PubMed: 14586325]
- Witkin 2003 . Witkin SS, Vardhana S, Yih M, Doh K, Bongiovanni AM, Gerber S. Polymorphism in intron 2 of the fetal interleukin-1 receptor antagonist genotype influences midtrimester amniotic fluid concentrations of interleukin-1 beta and interleukin-1 receptor antagonist and pregnancy outcome. *American Journal of Obstetrics and Gynecology*. 2003; 189(5):1413–7. [PubMed: 14634579]

References to other published versions of this review

- Brocklehurst 1998 . Brocklehurst P, Hannah M, McDonald H. Interventions for treating bacterial vaginosis in pregnancy. *Cochrane Database of Systematic Reviews*. 1998; (Issue 4)
- CDSR 2005 . McDonald H, Brocklehurst P, Parsons J. Antibiotics for treating bacterial vaginosis in pregnancy. *Cochrane Database of Systematic Reviews*. 2005; Issue 1 [Art. No.: CD000262. DOI: 10.1002/14651858.CD000262.pub2].

* *Indicates the major publication for the study*

PLAIN LANGUAGE SUMMARY

Antibiotics for treating bacterial vaginosis in pregnancy

Antibiotics during pregnancy for overgrowth of abnormal bacteria in the birth canal does not reduce the risk of babies being born too early.

Bacteria are normally present in the birth canal and are useful in maintaining the health of the vagina. However, if the numbers of abnormal bacteria increase, this may cause an unpleasant discharge and may cause some babies to be born too early. The review of 15 trials, involving 5888 women, found that antibiotics given to pregnant women reduced this overgrowth of bacteria, but did not reduce the numbers of babies who were born too early. The effect of earlier treatment needs to be studied in further trials.